vimarsana.com

Page 7 - நம்பகத்தன்மை வாழ்க்கை அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global $1 78 Bn Rituximab Biosimilars Forecast Market, 2019-2023F, 2025F & 2030F

Share this article Share this article ResearchAndMarkets.com s offering. Rituximab Biosimilars Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global rituximab biosimilars market. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA and Intas Biopharmaceuticals Ltd. The global rituximab biosimilars market is expected to decline from $1.84 billion in 2019 to $1.78 billion in 2020 at a compound annual growth rate (CAGR) of -3.22%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in

Global Biosimilar Monoclonal Antibodies Market Report 2020-2030: COVID-19 Impact, Growth and Changes - Press Release

Global Biosimilar Monoclonal Antibodies Market Report 2020-2030: COVID-19 Impact, Growth and Changes ResearchAndMarkets.com s offering. Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar monoclonal antibodies market. Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited. The global biosimilar monoclonal antibodies market is expected to decline from $3.21 billion in 2019 to $3.04 billion in 2020 at a compound annual growth rate (CAGR) of -5.18%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activitie

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.